By Metformin is the most widely prescribed diabetes medication on the planet. In the United States alone, it accounts for over 90 million prescriptions annually. It’s been in clinical use for over 60 years, is on the WHO’s List of Essential Medicines, costs pennies per pill in generic form, and has one of the most extensive safety records of any drug in modern medicine.
It’s also frequently misunderstood by the people taking it. Patients are often told to take it without a clear explanation of what it does, why it works, what to expect, and what its real risks are. This article covers all of that – the mechanism, the benefits, the side effects, the interactions, and the emerging evidence that metformin may do considerably more than just lower blood sugar.
What Metformin Is and Where It Came From
Metformin belongs to a drug class called biguanides. It’s derived from guanidine compounds found in the French lilac plant (Galega officinalis), which was used in medieval European medicine for symptoms resembling diabetes. The guanidine compounds were found to lower blood sugar in the 1920s, but early versions were too toxic for clinical use.
Metformin itself was developed in the 1950s by French physician Jean Sterne, who named it Glucophage (“glucose eater”). It was widely used in Europe from the 1960s but wasn’t approved in the United States until 1995, primarily due to regulatory caution following the withdrawal of a related biguanide (phenformin) for causing lactic acidosis – a risk metformin shares to a much lesser degree.
Today metformin is universally recommended as the first-line pharmacological treatment for type 2 diabetes by the American Diabetes Association, the European Association for the Study of Diabetes, and virtually every major diabetes guideline globally.
How Metformin Works: The Mechanisms
Metformin’s mechanism of action is more complex than most patients are told – and more interesting than a simple “it lowers blood sugar.”
Primary Mechanism: Hepatic Glucose Production
The liver is the body’s glucose factory. During overnight fasting and between meals, the liver continuously releases glucose into the bloodstream (hepatic glucose production/gluconeogenesis) to maintain blood sugar levels. In type 2 diabetes, this hepatic glucose output is inappropriately elevated – the liver keeps releasing glucose even when blood sugar is already high.
Metformin’s primary effect is suppressing this excessive hepatic glucose production. It does this primarily by activating an enzyme called AMP-activated protein kinase (AMPK) in liver cells. AMPK is a cellular energy sensor – when it’s activated, it signals the cell to conserve energy and stop energy-expensive processes like gluconeogenesis. By activating AMPK, metformin essentially tells the liver to stop producing so much glucose.
Secondary Mechanisms
Improved insulin sensitivity: Metformin improves the responsiveness of muscle and fat cells to insulin – enhancing glucose uptake from the bloodstream after meals.
Gut effects: Metformin also has significant effects in the gastrointestinal tract – it slows glucose absorption from the gut, which blunts post-meal blood sugar spikes. Recent research suggests gut-mediated effects may be more important than previously recognized.
Gut microbiome: Metformin substantially alters the gut microbiome composition, and some researchers believe this contributes meaningfully to its metabolic effects – though this is still being characterized.
GLP-1: Metformin increases circulating levels of GLP-1 (glucagon-like peptide-1), an incretin hormone that stimulates insulin secretion and suppresses appetite.
Unlike insulin and most other diabetes drugs, metformin does not directly stimulate insulin secretion. This means it does not cause hypoglycemia (dangerously low blood sugar) when used alone – a significant safety advantage.
What Metformin Does and Doesn’t Do
What it does:
- Lowers fasting blood glucose and HbA1c (typically by 1-2 percentage points)
- Reduces hepatic glucose output
- Improves insulin sensitivity
- Modest weight stabilization (not weight loss, but less weight gain than some other diabetes medications)
- Modest cardiovascular benefit – the landmark UKPDS trial found metformin reduced MI risk by 39% in overweight patients with type 2 diabetes, a finding that has driven its preferred status
What it doesn’t do:
- It does not stimulate insulin secretion (so it doesn’t cause hypoglycemia alone)
- It does not cause weight gain (unlike sulfonylureas and insulin)
- It does not cure diabetes or halt its progression indefinitely
Who Takes Metformin
Type 2 diabetes: First-line treatment, typically started at diagnosis alongside lifestyle modification. Most people with type 2 diabetes who can tolerate it remain on metformin as a foundation of their regimen even as other drugs are added.
Prediabetes: The ADA recommends considering metformin for people with prediabetes, particularly those with BMI ≥35, those under 60, and women with prior gestational diabetes. The Diabetes Prevention Program showed metformin reduced progression from prediabetes to diabetes by 31% (lifestyle intervention reduced it by 58%).
PCOS (Polycystic Ovary Syndrome): Metformin is commonly used off-label in PCOS to improve insulin resistance, regulate menstrual cycles, and support fertility – though it’s not FDA-approved for this indication.
Gestational diabetes: Used in some cases as an alternative or adjunct to insulin, though insulin remains the preferred first-line agent.
Side Effects: What to Actually Expect
Gastrointestinal Side Effects (Very Common)
GI side effects are the most common reason people stop metformin. Nausea, diarrhea, abdominal cramping, and bloating affect approximately 20-30% of people when starting, particularly at higher doses.
How to minimize them:
- Start at a low dose (500mg once daily) and increase gradually over weeks
- Take with food – always. Taking metformin on an empty stomach dramatically increases GI side effects.
- The extended-release formulation (metformin ER or XR) has significantly lower GI side effect rates than immediate-release at equivalent doses – worth requesting if standard metformin is causing persistent problems
- For most people, GI symptoms are worst in the first 2-4 weeks and substantially improve as the body adjusts
Vitamin B12 Deficiency (Important, Underrecognized)
This is the most clinically significant long-term effect of metformin and the one most frequently missed. Metformin reduces vitamin B12 absorption in the terminal ileum by approximately 30% through a mechanism involving calcium-dependent membrane transporters. Studies find that 10-30% of people on long-term metformin have biochemical B12 deficiency.
B12 deficiency matters because it can cause peripheral neuropathy (tingling, numbness in hands and feet) – which can be confused with diabetic neuropathy. The tragedy is that someone can be told their neuropathy is from diabetes and have their diabetes medications adjusted when the actual cause is metformin-induced B12 deficiency that’s entirely correctable.
The ADA Standard of Care recommends: Periodic B12 monitoring for all patients on long-term metformin. If you’ve been on metformin for more than 2-3 years and have never had B12 checked, ask your doctor for a B12 level.
Lactic Acidosis (Rare but Serious)
Metformin can, in specific circumstances, cause lactic acidosis – a buildup of lactic acid in the blood that can be life-threatening. This is rare (approximately 3 cases per 100,000 patient-years) and occurs almost exclusively in people with significant renal impairment (who cannot clear metformin adequately), severe hepatic disease, severe heart failure, or severe acute illness causing tissue hypoxia.
This is why metformin is contraindicated in:
- eGFR below 30 mL/min/1.73m² (dose reduction recommended when eGFR 30-45)
- Active or progressive hepatic disease
- Acute illness with risk of dehydration or poor perfusion
- Administration of iodinated contrast dye in certain circumstances (temporary hold required)
Routine use in people with normal or mildly reduced kidney function carries negligible lactic acidosis risk.
Metallic Taste
Some people notice a metallic or bitter taste, particularly in the first weeks of taking metformin. This is harmless and usually diminishes over time.
What to Know About Timing and Dosing
Starting dose: Typically 500mg once or twice daily with meals, increased by 500mg every 1-2 weeks as tolerated.
Usual maintenance dose: 1,000-2,000mg per day, typically in divided doses with meals. The maximum dose is 2,550mg per day, though most patients achieve adequate effect at 2,000mg.
Extended-release (ER/XR): Same efficacy as immediate-release, better GI tolerability, can often be taken once daily (usually with the evening meal). Generic extended-release is widely available.
Timing: Always take with food. Consistency of timing matters less than the with-food requirement.
Missed dose: Take as soon as remembered unless close to the next dose. Do not double up.
Contraindications for day of and day before:
- Day of surgery (hold due to fasting and anesthesia risk)
- Before IV contrast dye studies in people with eGFR below 60 – hold the day of and for 48 hours after
The Emerging Research: Metformin Beyond Diabetes
Metformin has attracted substantial interest as a potential longevity and anti-aging drug, based on epidemiological observations and laboratory data.
Cancer: Multiple observational studies find lower rates of several cancers in diabetic patients taking metformin versus those on other diabetes medications. The AMPK activation that underlies metformin’s glucose-lowering effect also inhibits mTORC1 – a signaling hub that promotes cell growth and is frequently overactivated in cancer cells. Randomized trials are underway testing metformin as a cancer prevention and treatment adjunct.
Aging: The TAME trial (Targeting Aging with Metformin) – a large NIH-funded randomized trial – is currently testing whether metformin can delay age-related diseases in non-diabetic adults, based on animal data showing lifespan extension and data from diabetic cohorts suggesting slower aging-associated disease accumulation compared to non-diabetic populations.
Cardiovascular: Beyond the UKPDS finding, recent large analyses confirm lower cardiovascular event rates in metformin-treated patients versus other oral diabetes medications, partly independent of glucose lowering.
These are promising directions but the current evidence supports metformin for diabetes and prediabetes – not yet as a general anti-aging intervention outside a research context.
Frequently Asked Questions
Will metformin make me lose weight? Metformin is weight-neutral to modestly weight-reducing in most people – distinctly better than insulin and sulfonylureas, which tend to cause weight gain. The average weight change is modest (1-3 kg loss in some studies, neutral in others). It is not a weight loss drug in the way GLP-1 receptor agonists (semaglutide, tirzepatide) are – those produce significantly greater weight reduction.
Do I have to take metformin forever? Many people with type 2 diabetes remain on metformin long-term as a cornerstone of their regimen. However, significant lifestyle changes (substantial weight loss, major dietary improvement, regular exercise) can sometimes allow dose reduction or even discontinuation in people with well-controlled diabetes – under medical supervision with close monitoring. This should never be done without discussing it with your doctor.
Can I drink alcohol on metformin? Moderate alcohol is generally compatible with metformin. Heavy alcohol use is not – it increases the (already small) risk of lactic acidosis and can cause dangerous hypoglycemia when combined with blood-sugar-lowering effects. Binge drinking while on metformin is specifically contraindicated.
My kidneys aren’t great. Can I still take metformin? Metformin requires dose adjustment or avoidance with reduced kidney function: eGFR 45-59 – continue with monitoring; eGFR 30-44 – reduce dose, use with caution; eGFR below 30 – contraindicated. If you have CKD, your prescriber should be monitoring your eGFR at least annually and adjusting accordingly.
Why do I need to stop metformin before a CT scan? Some CT scans use iodinated contrast dye, which can temporarily impair kidney function. Since metformin is cleared by the kidneys, impaired renal clearance could theoretically increase lactic acidosis risk. Current guidelines recommend holding metformin for 48 hours after contrast administration in people with eGFR below 60, or in any patient if acute kidney injury develops after the scan. Your radiology or prescribing team will give specific instructions.
Disclaimer
This article is for educational purposes only and does not constitute medical advice. Metformin should be prescribed and managed by a qualified healthcare provider. Do not start, stop, or adjust metformin based on this content without medical supervision.
References
- American Diabetes Association. Standards of medical care in diabetes – 2024. Diabetes Care. 2024;47(Suppl 1). https://doi.org/10.2337/dc24-S001
- Knowler WC, et al. Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin (DPP). New England Journal of Medicine. 2002;346(6):393-403. https://doi.org/10.1056/NEJMoa012512
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. 1998;352(9131):854-865. https://doi.org/10.1016/S0140-6736(98)07037-8
- Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nature Reviews Endocrinology. 2019;15(10):569-589. https://doi.org/10.1038/s41574-019-0242-2
- de Jager J, Kooy A, Lehert P, et al. Long-term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency. BMJ. 2010;340:c2181. https://doi.org/10.1136/bmj.c2181
- Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metabolism. 2016;23(6):1060-1065. https://doi.org/10.1016/j.cmet.2016.05.011
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Metformin. https://www.niddk.nih.gov
- MedlinePlus – National Library of Medicine. Metformin. https://medlineplus.gov/druginfo/meds/a696005.html
- Inzucchi SE, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012;35(6):1364-1379. https://doi.org/10.2337/dc12-0413
- FDA. Metformin drug label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf